Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 3D-20 is the variable domain of the kappa light chain in human antibodies, encoded by the IGKV3D-20 gene. It contributes to the specificity and diversity of immunoglobulin molecules by participating in antigen recognition, forming part of the antigen-binding site along with heavy chain variable domains. The variable domains are generated by V-(D)-J recombination and somatic hypermutation processes during B cell development, enabling affinity maturation. This domain is integral to humoral immunity, as it enables B lymphocytes to generate antibodies capable of binding to a vast array of antigens, including pathogens and abnormal self molecules. While the diversity of immunoglobulin variable domains is crucial for immune response, IGKV3D-20 itself is not a direct therapeutic target; instead, it represents one of many immunoglobulin gene segments contributing to antibody repertoire[5][3][2][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 3D-20 (IGKV3D-20).